GlassScriptPhysician profile
Renee Ellis
NPI 1134391733
$39,828.71
in general payments reported to CMS, 2019-2025
33 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,075 · 2020: $760 · 2021: $5,150 · 2022: $5,382 · 2023: $7,494 · 2024: $13K · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $3,786 · Travel and Lodging: $2,399 · Consulting Fee: $1,552 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,700.00 |
| Food and Beverage | $3,786.30 |
| Travel and Lodging | $2,398.51 |
| Consulting Fee | $1,552.00 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $34,385.97 | 2019-2025 | |
| Nxstage Medical, INC. | $717.58 | 2019-2025 | Nxstage System One |
| Astrazeneca Pharmaceuticals LP | $565.65 | 2020-2025 | Farxiga, Lokelma, Evusheld |
| Calliditas Therapeutics US INC. | $470.61 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $446.96 | 2019-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $390.66 | 2019-2025 | Velphoro, Nxstage System One, Velphoro |
| Amgen INC. | $348.07 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $329.34 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $252.51 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $194.23 | 2021-2025 | Acthar |
| Glaxosmithkline, LLC. | $177.60 | 2019-2024 | Benlysta, Jesduvroq |
| Travere Therapeutics, INC. | $176.72 | 2022-2025 | |
| Abbott Laboratories | $165.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $160.43 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $154.59 | 2022-2024 | Lupkynis |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $111.56 | 2019-2024 | Vafseo |
| Novo Nordisk INC | $95.14 | 2024-2025 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $82.26 | 2021-2024 | Injectafer |
| Mallinckrodt Enterprises LLC | $82.25 | 2019 | |
| Alexion Pharmaceuticals, INC. | $70.73 | 2019-2024 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $56.25 | 2021-2023 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.89 | 2023-2025 | Jardiance |
| Horizon Therapeutics Plc | $53.73 | 2021-2022 | |
| Cormedix INC. | $44.30 | 2024 | Defencath |
| Scpharmaceuticals INC. | $41.64 | 2025 | |
| Lundbeck LLC | $34.61 | 2019 | |
| Hollister Incorporated | $34.23 | 2023 | New Image, Adapt Ceraring |
| Opko Pharmaceuticals, LLC | $29.58 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $26.15 | 2025 | Empaveli |
| Ardelyx, INC. | $26.12 | 2025 | Ibsrela |
| Kyowa Kirin, INC. | $18.09 | 2023 | Crysvita |
| Pharmacosmos Therapeutics INC. | $15.93 | 2022 | |
| Shire North American Group INC | $15.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.